Cerenkov luminescence imaging (CLI) is a novel imaging modality to study charged
particles with optical methods by detecting the Cerenkov luminescence produced in tissue …

Intact antibodies and their truncated counterparts (eg, Fab, scFv fragments) are generally
exquisitely specific and selective vectors, enabling recognition of individual cancer …

Bone sarcomas are devastating primary bone cancers that mostly affect children, young
adults, and the elderly. These aggressive tumors are associated with poor survival, and …

Cerenkov luminescence is a blue-weighted emission of light produced by a vast array of
clinically approved radioisotopes and LINAC accelerators. When β particles (emitted during …

Medical radioisotopes produce Cerenkov luminescence (CL) from charged subatomic
particles (β+/−) traveling faster than light in dielectric media (eg, tissue). CL is a blue …

Rationale: Cerenkov luminescence (CL) is produced by medical radioisotopes when
charged particles (β+/-) travel faster than light in a dielectric medium (eg tissue). CLs blue …

The use of Cerenkov radiation to activate nanoparticles in situ was recently shown to control
cancerous tumor growth. Although the methodology has been demonstrated to work, to …

Cerenkov luminescence imaging (CLI) is a promising approach to image-guided surgery
and pathological sampling. It could offer additional advantages when combined to whole …

Synaptophysin is expressed on fibrogenic hepatic myofibroblasts. C1–3 is a single chain
human antibody (scAb) that binds specifically to synaptophysin on hepatic myofibroblasts …

Here, we describe immuno-Cerenkov luminescence imaging (immuno-CLI) with a specific
monoclonal antibody-based tracer for the detection of prostate tumors, which is used in …